Sentinel Lymph Node Biopsy in Melanoma: Overview and Updates
Adrian Mansini, Shah Aarohi, Mario Della Mura, Joana Sorino, Gerardo Cazzato, Alessio Giubellino
TL;DR
This paper reviews the changing role of sentinel lymph node biopsy in melanoma treatment and staging.
Contribution
The paper provides an updated overview of sentinel lymph node biopsy's role in melanoma management amidst new therapies.
Findings
SLNB remains valuable for staging and may offer therapeutic benefit.
Patient selection for SLNB requires evaluation of risk factors and adjuvant therapy benefits.
Ongoing controversies exist regarding optimal use of SLNB in melanoma management.
Abstract
The role of regional lymph nodes in melanoma metastasis has long been recognized. This review will detail the evolving role of sentinel lymph node biopsy (SLNB) in melanoma management in the era of adjuvant therapies. We analyze key themes and findings from recent publications, highlighting both areas of consensus and ongoing controversies. While the landscape of melanoma management continues to evolve with the advent of novel therapeutic combinations, SLNB remains a valuable tool for staging and potentially provides therapeutic benefit. However, optimal patient selection for SLNB requires careful consideration of individual risk factors and benefits of adjuvant therapy.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCutaneous Melanoma Detection and Management · Melanoma and MAPK Pathways · CAR-T cell therapy research